Skip to main content

Day: May 14, 2020

Atreca Reports First Quarter 2020 Financial Results and Recent Corporate Developments

SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2020, and provided an overview of recent developments.“While the COVID-19 pandemic has presented unexpected challenges, we continue to execute on our pipeline and business strategy, and we look forward to further progress throughout 2020,” said John Orwin, Chief Executive Officer. “Patients continue to be enrolled and treated in our Phase 1b dose-escalation clinical trial evaluating ATRC-101 in multiple solid tumors. In addition, we believe our recently announced alliance with BeiGene...

Continue reading

Laredo Petroleum Announces 1-For-20 Reverse Stock Split

TULSA, Okla., May 14, 2020 (GLOBE NEWSWIRE) — Laredo Petroleum, Inc. (NYSE: LPI) (“Laredo” or “the Company”), today announced that at the Company’s Annual Meeting, its stockholders voted to approve a proposal authorizing the Company, at the discretion of the Board of Directors, to effect (i) a reverse stock split of the Company’s common stock at a ratio ranging from 1-for-5 to 1-for-20 of shares currently outstanding and (ii) a corresponding reduction in the number of authorized shares of the Company’s common stock.Following the Company’s Annual Meeting, the Board of Directors approved a 1-for-20 reverse stock split ratio. The reverse stock split is expected to become effective on or about June 1, 2020. If completed, the Company’s stockholders will receive one new share of Laredo...

Continue reading

Bionano Genomics to Report First Quarter 2020 Financial Results on June 18, 2020

SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that the company is relying on the order issued by the U.S. Securities and Exchange Commission to delay the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 due to circumstances related to the COVID-19 pandemic. The company plans to file the Form 10-Q and report its financial results for the quarter ended March 31, 2020 on June 18, 2020. In addition, due to uncertainties regarding the duration and impact of the COVID-19 pandemic, the company is suspending any guidance, anticipated timelines or other outlooks previously provided...

Continue reading

Image Sensing Systems, Inc. Announces 2020 First Quarter Results

SAINT PAUL, Minn., May 14, 2020 (GLOBE NEWSWIRE) — Image Sensing Systems, Inc. (Nasdaq: ISNS) today announced results for its quarter ended March 31, 2020.First Quarter 2020 Financial SummaryFirst quarter royalties were $2.1 million, an increase of 20 percent from the same period in the prior year.First quarter product sales were $1.1 million, a decrease of 35 percent from the same period in the prior year.Operating expenses totaled $2.8 million in the first quarter of 2020, an increase of 23 percent from the prior year period.Capitalized software costs in the first quarter were $22,000 compared to $419,000 in the prior year period.Net loss for the first quarter of 2020 totaled $111,000 compared to net income of $308,000 for the same period in the prior year.Cash balance increased to $5.4 million, up from $5.1 million at the end...

Continue reading

ECN Capital Reports US$0.06 in Adjusted Earnings per Common Share in Q1-2020

TORONTO, May 14, 2020 (GLOBE NEWSWIRE) — ECN Capital Corp. (TSX: ECN) (“ECN Capital” or the “Company”) today reported financial results for the three-month period ended March 31, 2020.For the three-month period ended March 31, 2020, ECN Capital reported Adjusted net income applicable to common shareholders from continuing operations of $14.5 million or $0.06 per share (basic) versus $18.5 million or $0.08 per share (basic) for the previous three-month period ended December 31, 2019 and $12.6 million or $0.05 per share (basic) for the same period last year.“ECN had strong Q1 earnings of $0.06, in line with our guidance of $0.06 – $0.07,” said Steven Hudson, CEO of ECN Capital Corp. “We never expected to have the sort of stress test we are all getting from Covid-19, but we are very pleased with the resiliency of each of our...

Continue reading

IntelGenx Reports First Quarter 2020 Financial Results

SAINT LAURENT, Quebec, May 14, 2020 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX V:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today reported financial results for the first quarter ended March 31, 2020. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.2020 First Quarter Financial Summary:Revenue was $202,000, compared to $416,000 in the 2019 first quarterAdjusted EBITDA was ($1.9 million), compared to ($2.1 million) in Q1-2019Cash and short-term investments totaled $4.4 million as at March 31, 2020Recent Developments:Announced a performance improvement program focused on generating near-term revenue, preserving the Company’s resources, extending...

Continue reading

CohBar Reports First Quarter 2020 Financial Results and Provides Business Update

MENLO PARK, Calif., May 14, 2020 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the first quarter ended March 31, 2020.“I am pleased to share with you that since my arrival at CohBar last May, we have expanded the number of programs from two to five with the newest targeting COVID-19 associated acute respiratory distress syndrome (ARDS),” said Steven Engle, CohBar’s Chief Executive Officer. “Recently, we announced that we have a new target for our CB5064 apelin agonist program, which is COVID-19 associated ARDS, an underlying disease that lacks adequate therapies. We are excited because published preclinical studies have shown that apelin can reduce the...

Continue reading

Eton Pharmaceuticals Announces First Quarter 2020 Financial Results

DEER PARK, Ill., May 14, 2020 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the first quarter ended March 31, 2020 and provided an update on business progress.“The first quarter was an exciting period for Eton. We acquired marketing rights to orphan drug Alkindi Sprinkle and strengthened our balance sheet with an additional $9.8 million of liquidity,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “While COVID-19 has impacted our Biorphen commercial launch, we remain in a strong financial position and we look forward to the potential for multiple additional product launches later this year.”First Quarter MilestonesAcquired U.S. marketing rights to Alkindi® Sprinkle. Eton acquired...

Continue reading

PeerStream Name Change to Paltalk, Inc. and New Ticker Symbol, “PALT” Effective Friday, May 15, 2020

NEW YORK, NY, May 14, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — PeerStream, Inc. (“PeerStream,” the “Company,” “we,” “our” or “us”) (OTCQB: PEER), a leading communications software innovator that powers multimedia social applications and developer of secure communications software, today announced that the Company’s corporate name has been changed from “PeerStream, Inc.” to “Paltalk, Inc.,” effective Friday, May 15, 2020, and that the change of its ticker symbol from “PEER” to “PALT” has been approved by the Financial Industry Regulatory Authority (FINRA). The Company’s common stock will continue to trade on the OTC Markets and begin trading under the new ticker symbol (OTCQB: PALT) (CUSIP 69764K106), effective at the opening of trading hours on Friday, May 15, 2020.As previously announced, the corporate name change reflects...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.